Maxwell Lee

Maxwell Lee

Auto-generated profile, based on publicly available information

Maxwell Lee

Department of Otolaryngology—Head and Neck Surgery Stanford University Palo Alto California USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2021 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
MLMaxwell Y Lee
Maxwell Y Lee
YRYvette Robbins
Yvette Robbins
CSCem Sievers
Cem Sievers
JFJay Friedman
Jay Friedman
HSHoussein Abdul Sater
Houssein Abdul Sater
CAClint Allen
Clint Allen
Background As heterogeneous tumors develop in the face of intact immunity, tumor cells harboring genomic or expression defects that favor evasion from T-cell detection or elimination are selected. For patients with such tumors, T cell-based immunotherapy alone infrequently results in durable tumor control. Methods Here, we developed experimental models to study mechanisms of T-cell escape and demonstrated that resistance to T-cell killing can be overcome by the addition of natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) targeting programmed death ligand-1 (PD-L1). Results In engineered models of tumor heterogeneity, PD-L1 CAR-engineered NK cells (PD-L1 t-haNKs) prevented the clonal selection of T cell-resistant tumor cells observed with T-cell treatment alone in multiple models. Treatment of heterogenous cancer cell populations with T cells resulted in interferon gamma (IFN-γ) release and subsequent upregulation of PD-L1 on tumor cells that escaped T-cell killing through defects in antigen processing and presentation, priming escape cell populations for PD-L1 dependent killing by PD-L1 t-haNKs in vitro and in vivo. Conclusions These results describe the underlying mechanisms governing synergistic antitumor activity between T cell-based immunotherapy that results in IFN-γ production, upregulation of PD-L1 on T-cell escape cells, and the use of PD-L1 CAR-engineered NK cells to target and eliminate resistant tumor cell populations.

26 June 2022 in The Laryngoscope
Verified
Journal Article
Open access
MLMaxwell Y. Lee
Maxwell Y. Lee
MBMario Belfiglio
Mario Belfiglio
JZJohnathan Zeng
Johnathan Zeng
CFChristopher W. Fleming
Christopher W. Fleming
SKShlomo Koyfman
Shlomo Koyfman
JKJamie A. Ku
Jamie A. Ku
Objective: Organ preservation (OP) treatment for advanced laryngeal cancer has increased compared to primary total laryngectomy. Our study compares oncologic and functional outcomes between these approaches.Study Design: Retrospective cohort study.Setting: Single tertiary care institution.Methods: Retrospective review of patients receiving primary total laryngectomy or OP for laryngeal cancer between 1/1/2000 and 12/31/2018.Results: A total of 118 patients received primary total laryngectomy and 119 received OP. Overall survival was similar between total laryngectomy and OP. When stratified by T stage, disease‐free survival was worse among T3 patients receiving OP versus total laryngectomy. In T3 patients, 28 OP patients experienced local recurrence (28.9%) compared to 3 total laryngectomy patients (7.1%; p < 0.01). In total, 20 OP patients with local recurrence received salvage surgery. These patients had similar overall survival to patients who underwent initial total laryngectomy (TL). About 14 OP patients with local recurrence did not receive salvage surgery. About 89 (75.4%) TL patients achieved normal diet as compared to 64 (53.8%) OP patients (p < 0.001). In TL patients, 106 (89.8%) received primary or secondary tracheoesophageal‐prosthesis, 82 (77.4%) of whom achieved completely understandable speech.Conclusions: There was no difference in survival by treatment in T4 patients, possibly because of strict patient selection. However, disease‐free survival was worse in T3 patients receiving OP, likely due to a high local recurrence rate. Approximately 40% of patients with local recurrence were not eligible for salvage laryngectomy. TL patients had comparable swallowing and speech outcomes with OP patients.Level of Evidence: 3 Laryngoscope, 133:1122–1131, 2023

14 February 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
NMNavdeep Malik
Navdeep Malik
YKYoung-Im Kim
Young-Im Kim
HYHualong Yan
Hualong Yan
YTYu-Chou Tseng
Yu-Chou Tseng
WBWendy du Bois
Wendy du Bois
JHJing Huang
Jing Huang
Understanding functional interactions between cancer mutations is an attractive strategy for discovering unappreciated cancer pathways and developing new combination therapies to improve personalized treatment. However, distinguishing driver gene pairs from passenger pairs remains challenging. Here, we designed an integrated omics approach to identify driver gene pairs by leveraging genetic interaction analyses of top mutated breast cancer genes and the proteomics interactome data of their encoded proteins. This approach identified that PIK3CA oncogenic gain-of-function (GOF) and CBFB loss-of-function (LOF) mutations cooperate to promote breast tumor progression in both mice and humans. The transcription factor CBFB localized to mitochondria and moonlighted in translating the mitochondrial genome. Mechanistically, CBFB enhanced the binding of mitochondrial mRNAs to TUFM, a mitochondrial translation elongation factor. Independent of mutant PI3K, mitochondrial translation defects caused by CBFB LOF led to multiple metabolic reprogramming events, including defective oxidative phosphorylation, the Warburg effect, and autophagy/mitophagy addiction. Furthermore, autophagy and PI3K inhibitors synergistically killed breast cancer cells and impaired the growth of breast tumors, including patient-derived xenografts carrying CBFB LOF and PIK3CA GOF mutations. Thus, our study offers mechanistic insights into the functional interaction between mutant PI3K and mitochondrial translation dysregulation in breast cancer progression and provides a strong preclinical rationale for combining autophagy and PI3K inhibitors in precision medicine for breast cancer. Significance: CBFB-regulated mitochondrial translation is a regulatory step in breast cancer metabolism and synergizes with mutant PI3K in breast cancer progression.

1 June 2021 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
PDF file
RBRahul G. Baijal
Rahul G. Baijal
KWKarla E. Wyatt
Karla E. Wyatt
TSTeniola Shittu
Teniola Shittu
ECEugenia Y. Chen
Eugenia Y. Chen
EWEric Z. Wei
Eric Z. Wei
DMDeepak K. Mehta
Deepak K. Mehta

18 June 2021 in npj Vaccines
Verified
Journal Article
Open access
PDF file
MLMaxwell Y. Lee
Maxwell Y. Lee
SMSimon Metenou
Simon Metenou
DBDouglas E. Brough
Douglas E. Brough
HSHelen Sabzevari
Helen Sabzevari
KBKe Bai
Ke Bai
CAClint Allen
Clint Allen
Activation of antigen-specific T-lymphocyte responses may be needed to cure disorders caused by chronic infection with low-risk human papillomavirus (lrHPV). Safe and effective adjuvant therapies for such disorders are needed. The safety and efficacy of a novel gorilla adenovirus vaccine expressing a protein designed to elicit immune responses directed against HPV6 and HPV11, PRGN-2012, was studied using in vitro stimulation of T lymphocytes from patients with recurrent respiratory papillomatosis, in vivo vaccination studies, and therapeutic studies in mice bearing tumors expressing lrHPV antigen. PRGN-2012 treatment induces lrHPV antigen-specific responses in patient T lymphocytes. Vaccination of wild-type mice induces E6-specific T-lymphocyte responses without toxicity. In vivo therapeutic vaccination of mice bearing established HPV6 E6 expressing tumors results in HPV6 E6-specific CD8+ T-lymphocyte immunity of sufficient magnitude to induce tumor growth delay. The clinical study of PRGN-2012 in patients with disorders caused by chronic infection with lrHPV is warranted.

30 January 2026 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
MLMaxwell Y Lee
Maxwell Y Lee
ASAlistaire R Sherman
Alistaire R Sherman
LRLuis Martinez Ramirez
Luis Martinez Ramirez
MRMobeen Rahman
Mobeen Rahman
SZSabrina Zdravkovic
Sabrina Zdravkovic
VDVasu Divi
Vasu Divi
Background: Neoadjuvant PD-1/PD-L1 blockade yields robust efficacy in advanced cutaneous squamous cell carcinoma (cSCC), yet many patients fail to achieve a complete or major pathologic response. The reasons why some patients experience response but others do not are unclear. Methods: We profiled cSCC specimens before, after 1 dose, and after 3–4 doses of PD-1/PD-L1 blockade to uncover resistance mechanisms and predict therapeutic response. In total, 27 patients across three cohorts, including two phase II trials, were studied. We created 1.7 mm tissue-core microarrays and performed single-cell spatial transcriptomics, including spatial clustering, gene-set enrichment, and spatial correlation analyses. Results: After profiling all samples, six distinct spatial niches emerged, each differentially enriched in responders versus non-responders. A high antigen presentation niche, B/plasma cell enriched niche, and inflammatory keratinocyte niche were more frequent in responders, whereas proliferative keratinocyte, low antigen presentation myeloid, and fibroblast-rich epithelial–mesenchymal transition niches prevailed in non-responders. Notably, spatial niche profiling on pretreatment samples outperformed PD-L1 status in predicting pathologic response. Each niche displayed unique gene coexpression modules, suggesting niche-specific resistance mechanisms. Individual tumor analyses revealed varied immune evasion strategies, including defective interferon-induced antigen presentation, immunosuppressive myeloid environments, and epithelial–mesenchymal transition. Conclusions: Our single-cell spatial transcriptomic approach identifies six spatial niches that predict immunotherapy response better than PD-L1 status using only 1.7 mm tissue cores and may inform the development of biomarkers. Our results further underscore the heterogeneity of resistance mechanisms among cSCC patients, highlighting the need for tailored therapeutic strategies.